Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Poseida Therapeutics

Request full access

Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics

San Diego, United StatesFounded 2015Biotech & Life Sciences

About Poseida Therapeutics

Poseida Therapeutics, a clinical-stage biopharmaceutical company acquired by Roche in early 2025, is focused on developing next-generation cell and gene therapies. The company was founded in 2015 by Eric Ostertag, who previously founded and led another successful gene therapy company, Transposagen Biopharmaceuticals. His extensive background in molecular biology and gene-editing technologies directly shaped Poseida's strategic direction. The company's inception stemmed from a desire to overcome the limitations of early-generation gene engineering systems.

Poseida operates in the advanced therapeutics market, specifically targeting oncology and rare diseases. Its business model centers on the research, development, and eventual commercialization of its therapeutic candidates, serving patients with high unmet medical needs. Revenue generation is predicated on the successful clinical progression and regulatory approval of its product pipeline, a common model in the biopharmaceutical industry. The acquisition by Roche provides significant capital and resources to accelerate these developments.

The company's therapeutic portfolio is built upon a suite of proprietary genetic engineering platforms. A key differentiator is its non-viral piggyBac™ DNA Delivery System, which can deliver larger genetic payloads than traditional viral vectors, enabling more complex cellular modifications. This is complemented by the Cas-CLOVER™ Site-Specific Gene Editing System, a high-fidelity tool designed to make precise genetic edits with a lower risk of off-target mutations compared to some other CRISPR-based systems. Poseida has also developed a Booster Molecule technology aimed at improving the safety and efficacy of its therapies. Its pipeline includes allogeneic CAR-T cell therapies, which are derived from healthy donors rather than the patient, offering an 'off-the-shelf' treatment option that can be manufactured at scale. The company maintains control over its production process with in-house GMP (Good Manufacturing Practice) cell therapy manufacturing facilities.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2020

Poseida Therapeutics in the San Diego ecosystem

Live from Dealroom

The Poseida Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • California Institute for Regenerative Medicine

Series A3 investors entered at this stage

Series B and later9 investors entered at this stage

Employees mapped 78 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 21 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$53M

45 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Poseida Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.